“Must-Read” review from BiotechIntel Novo Nordisk – the world’s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment. Over $100,000,000 has been invested in developing this super-drug that threatens to make […]
Antriabio – which trades under the ticker “ANTB” – is about to bounce. If you’ve been following what I have to say I also think ANTB has 10-bagger potential (more about that in a moment). According to otcshortreport.com, about 50% of the shares that have traded in the last 30 days were sold short. A […]
ARCA Biopharma (ABIO) has been alerted as day-trading investment opportunity in real-time to our Twitter & Facebook followers at an around $.50/share. ABIO stock closed at $.68/share for the solid 36% in day-trading gains. Yesterday ABIO announced an update on a proposed, genetically-targeted clinical trial in atrial fibrillation (“AF”) of the Company’s lead developmental drug, Gencaro […]
edited on 02/02/2013: AntriaBio, Inc. (“AntriaBio”) announced that FINRA has approved a change of the Company’s stock ticker symbol. Effective today, the Company’s common shares will commence trading on the OTC Bulletin Board under the trading symbol “ANTB” ( OTCQB : ANTB ). The previous trading symbol was “FMYY” ( OTCQB : FMYY ). AntriaBio, […]
Sophisticated traders must take a look at iBio, Inc. (IBIO) as it seems that company has been overlooked as a solid player on the flu market. The high level of flu cases being reported across all states in the USA and Europe. Only in New York state a flu epidemic has hit more than 19,000 […]
Zoom Technologies (ZOOM) has been alerted on Twitter, as a trading opportunity, after company’s announcement of the execution of a definitive agreement pursuant to which it will sell its China-based manufacturing, sales and marketing, and R&D subsidiaries, and that the proceeds of the sale will be used for the purchase of additional U.S.-based businesses. Zoom […]
Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock found a bottom after sell-off (tax-losses) in the mid-December 2012 and now offers a solid trading opportunity. Besides technical analysis, there are more reasons to join this trade: CPRX announced on December 27th that it received a Nasdaq Staff Deficiency Letter for not compliance with the Minimum Bid Price requirement ($1/share) […]
Shipping Industry was one of the hottest stock market segments today. Some of the market analysts believe that the spike in share prices is a response to the Baltic Dry Index (BDI), which is going into a positive territory since been trampled at the 2012. Anyhow, looks like bottom has been formed in the one […]
Amicus Therapeutics (FOLD) has been profiled as a bounce play from December 31th, 2012. Since then FOLD shares gained over 50% (as of now) and have continued their march to the new highs. Today Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the […]
Aeterna Zentaris Inc. (AEZS) On December 28th Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. Optimistic market reaction on this announcement boosted AEZS shares […]
